Journal of Clinical Oncology
Articles in this Issue
Clinical outcomes of hypofractionated radiotherapy (5x5 Gy) with a simultaneous integrated boost (5x6 Gy) in locally advanced rectal cancer.
60 Background: Hypofractionated RT (5x5 Gy) with or without subsequent chemotherapy is a standard of care used at the National Institute of Oncology, Wars...
Cost-effectiveness of blood-based colorectal cancer screening: A simulation model incorporating real-world longitudinal adherence.
93 Background: Colorectal cancer (CRC) is a predominant cause of cancer-related mortality worldwide. Regular screening improves outcomes. However, despite...
Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.
341 Background: Based on the results of CheckMate-649 and ATTRACTION-4, nivolumab plus chemotherapy is the new standard of care as first-line treatment fo...
Comparative restricted mean survival time (RMST) analysis of survival in advanced hepatocellular carcinoma (aHCC) from pivotal phase III trials: IMbrave-150, ORIENT-32, CARES-310, HIMALAYA, and CM-9DW.
597 Background: In advanced hepatocellular carcinoma (aHCC), the evaluation of overall survival (OS) and progression-free survival (PFS) through restricte...
Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma.
580 Background: Lenvatinib stands out as a first-line therapy for individuals with advanced hepatocellular carcinoma (HCC). Concurrently, hepatic arterial...
Positive homologous recombination signature (HRDsig+) and the genomic landscape of intrahepatic cholangiocarcinoma (iCCA).
627 Background: Defective DNA repair has not been a major focus in iCCA clinical research. In this comprehensive genomic profiling (CGP) study, we queried...
Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.
410 Background: Neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is the standard of care for resectable locally advanced ESCC. SHR-1701,...
Phase II study of organ preservation (OP) in node-negative (NN) low rectal cancer (RC): Updated clinical and patient reported outcomes (PROs).
148 Background: Total mesorectal excision (TME) is a highly effective treatment for rectal cancer (RC) but is associated with significant morbidity and mo...
Influence of time to first therapy (TTFT) variable on survival outcomes of neoadjuvant chemotherapy versus upfront surgery approach in resectable pancreatic ductal adenocarcinoma.
720 Background: Evidence demonstrating overall survival (OS) benefit of neoadjuvant chemotherapy (NAC) followed by surgical resection over upfront surgica...
Patient-reported outcomes in physical, cognitive, and sexual health in early-onset gastrointestinal cancers (EOGIC).
72 Background: Incidence of early-onset (ages 18-49) gastrointestinal cancers is alarmingly increasing. To assess unmet needs in health-related quality of...
Comparison of screening outcomes associated with advanced precancerous lesion versus colorectal cancer sensitivity for a blood-based test: A simulation study.
89 Background: With estimates of over 150,000 incident and 50,000 fatal colorectal cancer (CRC) cases in 2024, efforts are ongoing to improve the national...
Development and validation of a prognostic model for advanced gastric and oesophageal carcinoma (AGOC) using individual patient data from two clinical trials.
499 Background: Estimating survival in advanced gastric and oesophageal carcinoma (AGOC) remains a significant challenge. We developed a prognostic model...
Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
423 Background: The efficacy of first-line treatment in advanced GC/GEJC patients (pts) with negative or low PD-L1 expression still needs to be improved....
A phase 2 study of amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) in metastatic pancreatic cancer.
TPS790 Background: Patients with advanced pancreatic adenocarcinoma (PDC) that progresses after first-line therapy face limited treatment options. Despite...
Costs of generic vs. branded nab-paclitaxel (nP) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with gemcitabine + nab-paclitaxel (GnP) in a real-world commercial database.
694 Background: In 2013, the FDA approved GnP for 1L treatment of mPDAC. The total cost of care (TCoC) to payers during treatment is driven by the cost of...
Ethnic and socioeconomic disparities in cancer-free and all-cause survival in cholangiocarcinoma patients under 60: A population-based study.
527 Background: Cholangiocarcinoma in individuals under 60 years of age is rare, and survival outcomes can vary based on ethnic and socioeconomic factors....
Genomic landscape study of esophago-gastric adenocarcinoma (EGAC) in young patients under the age of 30 years.
480 Background: Despite recent advances in treatment of EGAC, prognosis continues to be poor with reported 5-year survival of less than 30%. EGAC is more...
The safety and short-term efficacy of induction DCF plus nivolumab therapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
425 Background: Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (LA-ESC...
Quantitative amplification ratio for established and emerging biomarkers in gastroesophageal (GE) cancer.
470 Background: Gene copy number (CN) amplifications (amps) and/or protein overexpression in ERBB2 , EGFR...
Development and validation of a deep learning–based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: A retrospective multicenter cohort study.
298 Background: The current TNM staging system fails to provide adequate information for prognosis and adjuvant chemotherapy benefits in colorectal cancer...
Assessment of clinical value and barriers to use of new investigational targeted agents in the community setting: A study of claudin 18.2 and zolbetuximab.
500 Background: Rapid integration of novel agents in clinical practice can be lifesaving. However, community-based practices may experience extended adopt...
Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
666 Background: In the phase 3 CABINET trial (NCT03375320), cabozantinib (CABO) significantly prolonged median progression-free survival (PFS) compared to...
Can overall survival (OS) benefit be predicted from improvements in progression-free survival (PFS) for previously untreated metastatic colorectal cancer (mCRC)?
222 Background: With improvements in treatment of mCRC, OS maintains its gold standard efficacy measure but takes longer to mature than intermediate endpo...
Comparative analysis of racial disparities in social determinants of health among patients with GI cancer in the All of Us dataset.
804 Background: Social Determinants of Health (SDoH) are key factors in understanding disparities in cancer treatment and outcomes. Examining SDoH across...
Use of molecular residual disease (MRD) testing with measurement of circulating tumor DNA (ctDNA) post-operatively in stage II colon cancer (SIICC) in the community-based setting.
53 Background: 80% of adult oncology patients (pts) are treated in the community-based setting. Data on the implementation of emerging technologies such a...